1	Senate Bill No. 580
2	(By Senators Yost and Klempa)
3	
4	[Introduced February 21, 2011; referred to the Committee on
5	Health and Human Resources; and then to the Committee on the
6	Judiciary.]
7	
8	
9	
10	
11	A BILL to amend the Code of West Virginia, 1931, as amended, by
12	adding thereto a new article, designated §16-43-1, §16-43-2,
13	§16-43-3, §16-43-4, §16-43-5 and §16-43-6, all relating to
14	creating the Medication Therapy Management Act; and specifying
15	that fees for third-party providers pay for the therapy under
16	this act.
17	Be it enacted by the Legislature of West Virginia:
18	That the Code of West Virginia, 1931, as amended, be amended
19	by adding thereto a new article, designated §16-43-1, §16-43-2,
20	\$16-43-3, \$16-43-4, \$16-43-5 and \$16-43-6, all to read as follows:
21	ARTICLE 43. MEDICATION THERAPY MANAGEMENT ACT.
22	§16-43-1. Medication therapy management program.
23	
Ζ4	article is a program of drug therapy management furnished by a duly

1 licensed pharmacist under the West Virginia Code, and that is 2 designed to assure, with respect to targeted patients that 3 medications are appropriately used to optimize therapeutic outcomes 4 through improved medication use, and to reduce the risk of adverse 5 events, including adverse drug interactions. Such a program may 6 distinguish between services in ambulatory and institutional 7 settings. Upon implementation, third-party providers and state 8 health care providers shall pay a fee to pharmacy providers for 9 medication therapy management services. Targeted patients are 10 individuals who have at least one chronic disease, including, but 11 not limited to, diabetes, asthma, chronic obstructive pulmonary other chronic lung disorders, hypertension, 12 disease or 13 hyperlipidemia, congestive heart failure, chronic pain disorder or 14 behavioral health disorder, and are taking multiple drugs to treat 15 one or more such conditions. A patient with a prescription drug 16 therapy problem who is identified by the primary health care 17 provider and is eligible for medication therapy management services 18 under the plan, self-pay.

19 **§16-43-2**. Definition.

20 For purpose of this article:

"Medication therapy management" means the one-on-one provision 22 of the following pharmaceutical care services by a licensed 23 pharmacist to optimize the therapeutic outcomes of the patient's 24 medications. Working with the patient to develop a personal

1 medication record as part of a personal health record that contains 2 all prescribed and nonprescription drugs, herbal products, and 3 dietary supplements taken by the patient.

4 §16-43-3. Patient treatment.

5 "Medication therapy management" may include:

6 (a) Interviewing the patient to gather data, including 7 demographic information, general health and activity status, 8 medical history, medication history, immunization history, and to 9 collect the patient's personal assessment about his or her disease 10 or condition and medication use;

(b) Performing necessary clinical assessments of the patient's health status, including current or previous diseases or or conditions;

(c) Assessing patient values, preferences, quality of life, 5 goals of therapy, cultural issues, education level, language 6 barriers, literacy level and other characteristics affecting the 7 patient's communication skills that could affect patient outcomes; 8 (d) Monitoring and evaluating the patient's responses to his 19 or her medication therapies, including the safety and effectiveness 20 of those therapies;

(e) Assessing, identifying, prioritizing and developing a plan 22 for resolving medication-related problems related to the clinical 23 appropriateness of each medication, the appropriateness of the 24 dosage of each medication, including considerations of indications,

1 contra-indications, and potential adverse effects, adherence to
2 regimen, untreated diseases or conditions, medication costs, and
3 provider access considerations;

4 (f) Providing consultative services for the patient, 5 intervening to address medication-related issues, and, when the 6 pharmacist believes it will be beneficial to the patient's health, 7 referring the patient to his/her regular health care provider for 8 evaluation and additional referral(s);

9 (g) Communicating information to the primary health care 10 provider or other health care professionals, including consultation 11 on the selection of medications, suggestions to address identified 12 medication problems, updates on the patient's progress, and 13 recommended follow-up care;

14 (h) Providing education and training on the appropriate use of 15 medications and monitoring devices;

16 (i) Coaching patients to manage their own medications and 17 promote their wellness;

(j) Evaluating the patient's ability to detect symptoms that l9 could be attributed to adverse reactions or interactions from 20 medications;

(k) Monitoring, and assessing the results of a patient's laboratory testing, including those performed in the pharmacy setting;

24 (1) Increasing patient adherence to prescription medication

1 regimens through medication refill reminders, compliance aids (such 2 as pill boxes, timers, packaging, and calendaring, and other 3 appropriate and cost-effective interventions);

4 (m) Detection of adverse drug events, as well as overuse and 5 underuse of prescription and nonprescription products;

6 (n) Coordinating and integrating medication therapy management 7 services within the broader health care management services being 8 provided to the patient as recommended by the primary healthcare 9 provider and/or other healthcare professional or specialist;

(o) Performing follow-up MTM services for the maintenance and support of the patient, as recommended by the primary health care provider and/or other health care professional or specialist; and (p) Maintaining all necessary documentation, including the following and any other records required for compliance with state and federal laws and regulations pertaining to maintenance of

16 patient records:

17 (1) Patient demographics and basic identifying information;

18 (2) Subjective, meaning, patient-reported, information;

(3) Objective, meaning, service provider-based, observations 20 regarding known allergies, diseases, conditions, laboratory test 21 results, vital signs, physical exam results, review of systems, and 22 recorded medical diagnoses;

23 (4) Assessment of medication-related problems;

24 (5) Written care plan;

(6) Recorded collaborative communication with primary health
 2 care providers and other healthcare professionals;

3 (7) Patient-specific lists of actions to be followed in 4 tracking progress in medication self-management;

5 (8) Any relevant transition plan or scheduling of follow-up 6 visits and billing information, including level of patient care, 7 level of complexity and charges;

8 (9) Patient health and medication literacy assessment; and

9 (10) Patient's pharmacy encounter satisfaction survey.

10 (q) Providing the individual with a written or printed summary 11 of the results of such medication therapy management review 12 session.

13 §16-43-4. Reimbursement eligibility.

14 To be eligible for reimbursement for services provided under 15 this section, a pharmacist shall:

16 (a) Hold a valid and current license issued by the West 17 Virginia Board of Pharmacy;

18 (b) Have completed a structured and comprehensive education 19 program approved by the West Virginia Board of Pharmacy or the 20 American Council of Pharmaceutical Education for the provision and 21 documentation of pharmaceutical care management services that has 22 both clinical and didactic elements;

23 (c) Develop a structured written patient care process24 protocol; and

(d) Maintain an electronic patient record system for outcomes
 2 analysis and patient care.

3 §16-43-5. Evaluation.

4 The Board of Pharmacy shall evaluate the effect of medication 5 therapy management on quality of care, patient outcomes, and 6 program costs, and shall include a description of any savings 7 generated in the medical assistance and general assistance medical 8 care programs that can be attributable to this coverage. The 9 evaluation shall be submitted to the Legislature within two years 10 of the effective date of the legislation.

11 §16-43-6. Payment of fees.

12 (a) Upon implementation of this legislation, third-party 13 providers shall pay a fee to pharmacy providers for medication 14 therapy management services. These services may also be provided by 15 pharmacists on a self-pay basis when a patient does not have a 16 third-party provider.

17 (b)The fee shall be calculated using one or more quarter-18 hourly rates implemented by formal regulation that are designed to 19 reimburse the pharmacist or pharmacy based on time spent in 20 providing the medication therapy management services.

(c) Third-Party Plans shall pay the fee, separate from reimbursement for prescription drug product or dispensing services, any individual pharmacist or pharmacy participating in the plans that provides medication therapy management services.

NOTE: The purpose of this bill is to create a medication management therapy program and setting out the funding source for paying for the program.

The article is new; therefore, strike-throughs and underscoring have been omitted.